BHCM
SWTX

Brevan Howard Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Brevan Howard Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,680
Closed -$207K – 2009
2025
Q1 		$207K Sell
4,680
-3,814
-45% -$176K ﹤0.01% 972
2024
Q4 		$307K Sell
8,494
-265
-3% -$9.26K ﹤0.01% 765
2024
Q3 		$281K Sell
8,759
-3,678
-30% -$137K ﹤0.01% 880
2024
Q2 		$469K Buy
+12,437
New +$523K ﹤0.01% 633

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Brevan Howard Capital Management's SWTX Position: Q2 2025 in Review

Brevan Howard Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 4,680 shares — an estimated $207K sold.

Brevan Howard Capital Management first reported a position in SWTX in Q2 2024 and held it in 4 quarters. The position peaked at $469K in Q2 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Brevan Howard Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 4,680 SpringWorks Therapeutics shares in Q2 2025, an estimated $207K.
  • Brevan Howard Capital Management first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 4 quarters.
  • Brevan Howard Capital Management's SpringWorks Therapeutics position peaked at $469K in Q2 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Brevan Howard Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.